Timothy Benke
Concepts (558)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spasms, Infantile | 40 | 2026 | 138 | 8.200 |
Why?
| | Epileptic Syndromes | 37 | 2026 | 98 | 7.530 |
Why?
| | Rett Syndrome | 31 | 2026 | 43 | 7.430 |
Why?
| | Seizures | 23 | 2026 | 482 | 4.410 |
Why?
| | Epilepsy | 14 | 2025 | 389 | 2.700 |
Why?
| | Methyl-CpG-Binding Protein 2 | 11 | 2026 | 23 | 2.670 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 16 | 2026 | 229 | 2.370 |
Why?
| | Receptors, AMPA | 14 | 2024 | 148 | 2.140 |
Why?
| | Hippocampus | 23 | 2025 | 969 | 1.960 |
Why?
| | Long-Term Synaptic Depression | 4 | 2025 | 49 | 1.680 |
Why?
| | Receptors, Metabotropic Glutamate | 3 | 2025 | 37 | 1.650 |
Why?
| | Long-Term Potentiation | 10 | 2024 | 199 | 1.640 |
Why?
| | Vision Disorders | 9 | 2025 | 179 | 1.560 |
Why?
| | Severity of Illness Index | 14 | 2026 | 2945 | 1.310 |
Why?
| | Clinical Trials as Topic | 5 | 2024 | 1058 | 1.240 |
Why?
| | Synapses | 14 | 2024 | 438 | 1.200 |
Why?
| | Movement Disorders | 5 | 2023 | 70 | 1.180 |
Why?
| | Psychometrics | 12 | 2025 | 731 | 1.110 |
Why?
| | Calcium Channels, L-Type | 4 | 2025 | 118 | 1.110 |
Why?
| | Excitatory Postsynaptic Potentials | 12 | 2024 | 119 | 1.090 |
Why?
| | Cognition Disorders | 10 | 2020 | 541 | 1.050 |
Why?
| | Neurodevelopmental Disorders | 5 | 2025 | 226 | 1.050 |
Why?
| | Protein Phosphatase 2 | 2 | 2025 | 41 | 0.960 |
Why?
| | Electroencephalography | 16 | 2026 | 563 | 0.920 |
Why?
| | Loss of Function Mutation | 1 | 2025 | 46 | 0.890 |
Why?
| | Genetic Testing | 3 | 2025 | 480 | 0.890 |
Why?
| | CA1 Region, Hippocampal | 4 | 2024 | 49 | 0.860 |
Why?
| | Rats, Sprague-Dawley | 14 | 2025 | 2526 | 0.840 |
Why?
| | Neuropsychological Tests | 17 | 2020 | 1139 | 0.830 |
Why?
| | Anticonvulsants | 6 | 2023 | 246 | 0.830 |
Why?
| | Internationality | 1 | 2024 | 156 | 0.820 |
Why?
| | Kainic Acid | 10 | 2024 | 33 | 0.800 |
Why?
| | Child, Preschool | 39 | 2026 | 11837 | 0.800 |
Why?
| | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 4 | 2020 | 15 | 0.800 |
Why?
| | Child | 57 | 2026 | 22680 | 0.800 |
Why?
| | Brain Ischemia | 3 | 2021 | 360 | 0.780 |
Why?
| | Developmental Disabilities | 3 | 2025 | 281 | 0.770 |
Why?
| | Social Behavior | 3 | 2015 | 288 | 0.760 |
Why?
| | Autistic Disorder | 3 | 2022 | 217 | 0.740 |
Why?
| | Infarction, Posterior Cerebral Artery | 1 | 2021 | 3 | 0.690 |
Why?
| | Disease Models, Animal | 12 | 2025 | 4559 | 0.690 |
Why?
| | Schizophrenia | 2 | 2025 | 444 | 0.680 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2024 | 553 | 0.680 |
Why?
| | Caregivers | 9 | 2025 | 1070 | 0.680 |
Why?
| | Quality of Life | 11 | 2025 | 3195 | 0.670 |
Why?
| | Humans | 124 | 2026 | 145491 | 0.670 |
Why?
| | Rats | 22 | 2025 | 5581 | 0.670 |
Why?
| | Memory Disorders | 4 | 2014 | 198 | 0.660 |
Why?
| | Male | 79 | 2026 | 72817 | 0.590 |
Why?
| | Genetic Therapy | 1 | 2021 | 316 | 0.590 |
Why?
| | Communication | 5 | 2025 | 975 | 0.570 |
Why?
| | Phenotype | 14 | 2025 | 3157 | 0.570 |
Why?
| | Female | 81 | 2026 | 78763 | 0.560 |
Why?
| | Maze Learning | 3 | 2014 | 106 | 0.550 |
Why?
| | Adolescent | 43 | 2026 | 22485 | 0.540 |
Why?
| | Symptom Assessment | 1 | 2019 | 136 | 0.530 |
Why?
| | Infant | 24 | 2026 | 10064 | 0.530 |
Why?
| | Animals | 43 | 2025 | 38141 | 0.520 |
Why?
| | Neuronal Plasticity | 3 | 2018 | 306 | 0.520 |
Why?
| | Cerebral Cortex | 7 | 2021 | 471 | 0.490 |
Why?
| | Stroke | 2 | 2021 | 1272 | 0.490 |
Why?
| | Animals, Newborn | 11 | 2024 | 890 | 0.480 |
Why?
| | Speech Disorders | 3 | 2019 | 29 | 0.480 |
Why?
| | Genomics | 1 | 2021 | 834 | 0.470 |
Why?
| | Reproducibility of Results | 13 | 2025 | 3424 | 0.470 |
Why?
| | Parents | 7 | 2025 | 1404 | 0.460 |
Why?
| | Hair Cells, Vestibular | 4 | 2023 | 32 | 0.460 |
Why?
| | Surveys and Questionnaires | 13 | 2025 | 6070 | 0.460 |
Why?
| | Dementia | 6 | 2010 | 325 | 0.450 |
Why?
| | Nerve Tissue Proteins | 5 | 2026 | 590 | 0.420 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 5 | 2024 | 196 | 0.420 |
Why?
| | Young Adult | 23 | 2026 | 14192 | 0.400 |
Why?
| | Adult | 44 | 2026 | 40707 | 0.400 |
Why?
| | Adrenocorticotropic Hormone | 3 | 2023 | 147 | 0.400 |
Why?
| | Memantine | 4 | 2026 | 18 | 0.380 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 1769 | 0.380 |
Why?
| | Mutation | 14 | 2025 | 4093 | 0.340 |
Why?
| | Behavior, Animal | 1 | 2015 | 526 | 0.340 |
Why?
| | Nervous System Diseases | 2 | 2023 | 287 | 0.320 |
Why?
| | Glutamic Acid | 4 | 2007 | 256 | 0.320 |
Why?
| | Ion Channels | 4 | 2012 | 129 | 0.310 |
Why?
| | Chromosome Duplication | 2 | 2020 | 5 | 0.310 |
Why?
| | Autism Spectrum Disorder | 3 | 2026 | 420 | 0.310 |
Why?
| | Treatment Outcome | 14 | 2026 | 11831 | 0.310 |
Why?
| | Brain | 12 | 2026 | 2944 | 0.290 |
Why?
| | Basal Ganglia Diseases | 2 | 2009 | 9 | 0.290 |
Why?
| | Excitatory Amino Acid Agonists | 4 | 2015 | 42 | 0.290 |
Why?
| | Communication Disorders | 2 | 2025 | 13 | 0.280 |
Why?
| | Evoked Potentials | 4 | 2026 | 131 | 0.270 |
Why?
| | Genetic Association Studies | 2 | 2020 | 369 | 0.270 |
Why?
| | Motor Skills | 2 | 2026 | 104 | 0.270 |
Why?
| | Space Perception | 1 | 2008 | 82 | 0.260 |
Why?
| | Risk-Taking | 2 | 2009 | 325 | 0.260 |
Why?
| | Excitatory Amino Acid Antagonists | 2 | 2026 | 107 | 0.260 |
Why?
| | Evoked Potentials, Visual | 3 | 2023 | 42 | 0.260 |
Why?
| | Alzheimer Disease | 2 | 2020 | 631 | 0.250 |
Why?
| | Interneurons | 2 | 2025 | 125 | 0.250 |
Why?
| | Dystonia | 1 | 2007 | 28 | 0.250 |
Why?
| | Memory, Short-Term | 2 | 2008 | 272 | 0.250 |
Why?
| | Models, Neurological | 6 | 2005 | 250 | 0.240 |
Why?
| | Cholinesterase Inhibitors | 2 | 2010 | 47 | 0.240 |
Why?
| | Membrane Potentials | 6 | 2023 | 278 | 0.240 |
Why?
| | Brain Abscess | 1 | 2006 | 10 | 0.240 |
Why?
| | Calcium | 6 | 2023 | 1190 | 0.240 |
Why?
| | Exons | 2 | 2024 | 363 | 0.240 |
Why?
| | Amnesia | 2 | 2005 | 47 | 0.240 |
Why?
| | Neurons | 7 | 2023 | 1647 | 0.230 |
Why?
| | Gain of Function Mutation | 1 | 2026 | 34 | 0.230 |
Why?
| | Indans | 1 | 2005 | 13 | 0.230 |
Why?
| | Prosencephalon | 1 | 2005 | 54 | 0.230 |
Why?
| | Pregnanolone | 2 | 2024 | 34 | 0.230 |
Why?
| | Gamma Rhythm | 1 | 2025 | 8 | 0.230 |
Why?
| | Parkinson Disease | 6 | 2011 | 601 | 0.230 |
Why?
| | Aneurysm, Ruptured | 1 | 2005 | 38 | 0.220 |
Why?
| | Amnesia, Transient Global | 1 | 2005 | 1 | 0.220 |
Why?
| | Age Factors | 5 | 2020 | 3340 | 0.220 |
Why?
| | Amobarbital | 1 | 2005 | 2 | 0.220 |
Why?
| | Hydrocephalus | 2 | 2024 | 111 | 0.220 |
Why?
| | Fragile X Syndrome | 1 | 2026 | 119 | 0.220 |
Why?
| | Magnetic Resonance Imaging | 11 | 2010 | 3897 | 0.220 |
Why?
| | Twins, Monozygotic | 1 | 2025 | 134 | 0.220 |
Why?
| | Tissue Culture Techniques | 2 | 2015 | 82 | 0.220 |
Why?
| | Long QT Syndrome | 2 | 2022 | 69 | 0.220 |
Why?
| | Genetic Diseases, X-Linked | 2 | 2024 | 26 | 0.210 |
Why?
| | Delayed Diagnosis | 1 | 2025 | 100 | 0.210 |
Why?
| | Double-Blind Method | 7 | 2025 | 2060 | 0.210 |
Why?
| | Brain Diseases | 3 | 2023 | 153 | 0.210 |
Why?
| | Signal Transduction | 3 | 2024 | 5202 | 0.210 |
Why?
| | Frameshift Mutation | 1 | 2024 | 30 | 0.210 |
Why?
| | 5' Untranslated Regions | 1 | 2024 | 59 | 0.210 |
Why?
| | Endpoint Determination | 1 | 2024 | 85 | 0.210 |
Why?
| | Pyramidal Cells | 4 | 2024 | 80 | 0.210 |
Why?
| | Forkhead Transcription Factors | 1 | 2025 | 207 | 0.210 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2025 | 125 | 0.210 |
Why?
| | Patch-Clamp Techniques | 8 | 2015 | 289 | 0.210 |
Why?
| | Bias | 1 | 2025 | 198 | 0.210 |
Why?
| | Tetanus Toxin | 1 | 2004 | 6 | 0.210 |
Why?
| | Limbic Encephalitis | 1 | 2004 | 7 | 0.200 |
Why?
| | Mosaicism | 1 | 2024 | 73 | 0.200 |
Why?
| | Thalamus | 2 | 2021 | 127 | 0.200 |
Why?
| | Cannabinoids | 1 | 2026 | 184 | 0.200 |
Why?
| | Piperidines | 1 | 2005 | 221 | 0.200 |
Why?
| | Epilepsy, Temporal Lobe | 4 | 2005 | 38 | 0.200 |
Why?
| | Disability Evaluation | 1 | 2025 | 311 | 0.200 |
Why?
| | Hyperglycinemia, Nonketotic | 1 | 2024 | 56 | 0.200 |
Why?
| | Celiac Disease | 1 | 2007 | 310 | 0.200 |
Why?
| | Parvalbumins | 1 | 2023 | 26 | 0.200 |
Why?
| | Neurodegenerative Diseases | 1 | 2006 | 150 | 0.200 |
Why?
| | Cognition | 2 | 2020 | 1268 | 0.200 |
Why?
| | Ketamine | 1 | 2025 | 137 | 0.200 |
Why?
| | Cerebral Aqueduct | 1 | 2003 | 4 | 0.190 |
Why?
| | Congresses as Topic | 1 | 2024 | 223 | 0.190 |
Why?
| | Glycine | 1 | 2024 | 186 | 0.190 |
Why?
| | Olfactory Bulb | 1 | 2024 | 99 | 0.190 |
Why?
| | Ventriculostomy | 1 | 2003 | 24 | 0.190 |
Why?
| | Chromosomes, Human, X | 2 | 2023 | 76 | 0.190 |
Why?
| | Dendrites | 3 | 2007 | 104 | 0.190 |
Why?
| | Decision Making | 2 | 2009 | 979 | 0.190 |
Why?
| | Status Epilepticus | 1 | 2023 | 68 | 0.190 |
Why?
| | Hypnotics and Sedatives | 1 | 2005 | 224 | 0.190 |
Why?
| | Consensus | 1 | 2024 | 483 | 0.180 |
Why?
| | Learning | 1 | 2007 | 448 | 0.180 |
Why?
| | Calcinosis | 1 | 2004 | 235 | 0.180 |
Why?
| | Child Behavior | 2 | 2024 | 236 | 0.180 |
Why?
| | Checklist | 1 | 2023 | 111 | 0.180 |
Why?
| | Disorders of Excessive Somnolence | 1 | 2022 | 38 | 0.180 |
Why?
| | Anti-Anxiety Agents | 1 | 2022 | 47 | 0.180 |
Why?
| | Phosphorylation | 3 | 2015 | 1707 | 0.180 |
Why?
| | Sleep Wake Disorders | 2 | 2024 | 310 | 0.170 |
Why?
| | Vestibule, Labyrinth | 1 | 2023 | 91 | 0.170 |
Why?
| | Posterior Cerebral Artery | 1 | 2021 | 7 | 0.170 |
Why?
| | Ultrasonics | 1 | 2021 | 50 | 0.170 |
Why?
| | Neurologists | 1 | 2021 | 23 | 0.170 |
Why?
| | Acute Disease | 4 | 2015 | 1040 | 0.170 |
Why?
| | Receptors, GABA-A | 1 | 2022 | 137 | 0.170 |
Why?
| | Sodium Channel Blockers | 1 | 2021 | 23 | 0.170 |
Why?
| | Synaptic Transmission | 4 | 2023 | 292 | 0.170 |
Why?
| | Corpus Callosum | 2 | 2019 | 72 | 0.170 |
Why?
| | Vision, Ocular | 1 | 2021 | 47 | 0.170 |
Why?
| | Visual Pathways | 1 | 2021 | 61 | 0.160 |
Why?
| | In Vitro Techniques | 6 | 2013 | 1047 | 0.160 |
Why?
| | Subcellular Fractions | 2 | 2013 | 73 | 0.160 |
Why?
| | Intellectual Disability | 1 | 2022 | 178 | 0.160 |
Why?
| | Autonomic Nervous System Diseases | 2 | 2019 | 37 | 0.160 |
Why?
| | Athletic Injuries | 1 | 2007 | 571 | 0.160 |
Why?
| | Memory | 3 | 2008 | 297 | 0.160 |
Why?
| | Middle Aged | 22 | 2026 | 36176 | 0.160 |
Why?
| | Endoscopy | 1 | 2003 | 317 | 0.160 |
Why?
| | Electrophysiology | 5 | 2007 | 218 | 0.150 |
Why?
| | Follow-Up Studies | 9 | 2021 | 5426 | 0.150 |
Why?
| | Disease Progression | 3 | 2024 | 2862 | 0.150 |
Why?
| | Analysis of Variance | 5 | 2009 | 1304 | 0.150 |
Why?
| | Cyclins | 1 | 2020 | 79 | 0.150 |
Why?
| | Blotting, Western | 2 | 2015 | 1162 | 0.150 |
Why?
| | Precision Medicine | 2 | 2025 | 456 | 0.150 |
Why?
| | Mental Disorders | 2 | 2025 | 1157 | 0.150 |
Why?
| | Mutation, Missense | 4 | 2024 | 338 | 0.150 |
Why?
| | Predictive Value of Tests | 1 | 2024 | 2129 | 0.150 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2022 | 194 | 0.150 |
Why?
| | Action Potentials | 6 | 2023 | 502 | 0.140 |
Why?
| | Pediatrics | 1 | 2007 | 1121 | 0.140 |
Why?
| | Gene Duplication | 1 | 2019 | 69 | 0.140 |
Why?
| | Vagus Nerve Stimulation | 1 | 2019 | 28 | 0.140 |
Why?
| | Glutamates | 3 | 2023 | 66 | 0.140 |
Why?
| | Diet, Ketogenic | 1 | 2019 | 38 | 0.140 |
Why?
| | Mice | 9 | 2025 | 18338 | 0.140 |
Why?
| | Motor Activity | 2 | 2020 | 723 | 0.140 |
Why?
| | Face | 1 | 2020 | 177 | 0.140 |
Why?
| | Syndrome | 3 | 2020 | 380 | 0.140 |
Why?
| | Research Design | 1 | 2024 | 1134 | 0.140 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 5989 | 0.140 |
Why?
| | Judgment | 1 | 2018 | 66 | 0.130 |
Why?
| | Retrospective Studies | 10 | 2026 | 17269 | 0.130 |
Why?
| | Aphasia | 3 | 2004 | 24 | 0.130 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2018 | 82 | 0.130 |
Why?
| | Delphi Technique | 1 | 2019 | 333 | 0.130 |
Why?
| | Syncope, Vasovagal | 1 | 1997 | 6 | 0.130 |
Why?
| | Delusions | 1 | 1997 | 9 | 0.130 |
Why?
| | Epilepsy, Generalized | 1 | 1997 | 22 | 0.120 |
Why?
| | Gastrointestinal Diseases | 1 | 2019 | 221 | 0.120 |
Why?
| | Alternative Splicing | 1 | 2019 | 247 | 0.120 |
Why?
| | Cohort Studies | 5 | 2026 | 5992 | 0.120 |
Why?
| | Genetic Variation | 1 | 2021 | 988 | 0.120 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 587 | 0.120 |
Why?
| | Epilepsies, Partial | 1 | 1997 | 63 | 0.120 |
Why?
| | Protein Conformation | 1 | 2019 | 935 | 0.120 |
Why?
| | Time | 1 | 2015 | 86 | 0.110 |
Why?
| | Physicians | 1 | 2024 | 952 | 0.110 |
Why?
| | Brain Damage, Chronic | 1 | 1995 | 18 | 0.110 |
Why?
| | Time Factors | 9 | 2009 | 7171 | 0.110 |
Why?
| | Sex Factors | 2 | 2019 | 2110 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 368 | 0.110 |
Why?
| | Organ Culture Techniques | 2 | 2016 | 149 | 0.110 |
Why?
| | Meningitis, Bacterial | 1 | 1995 | 46 | 0.110 |
Why?
| | N-Methylaspartate | 2 | 1996 | 43 | 0.110 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2014 | 26 | 0.110 |
Why?
| | Lyme Disease | 1 | 1995 | 58 | 0.100 |
Why?
| | Calmodulin | 1 | 2014 | 69 | 0.100 |
Why?
| | X Chromosome Inactivation | 2 | 2025 | 25 | 0.100 |
Why?
| | Membrane Proteins | 3 | 2010 | 1164 | 0.100 |
Why?
| | Aged | 14 | 2024 | 26125 | 0.100 |
Why?
| | Models, Molecular | 1 | 2019 | 1614 | 0.100 |
Why?
| | Conotoxins | 1 | 1993 | 16 | 0.100 |
Why?
| | Spasm | 2 | 2023 | 21 | 0.100 |
Why?
| | Demyelinating Diseases | 1 | 1994 | 84 | 0.100 |
Why?
| | Infant, Newborn | 4 | 2024 | 6437 | 0.100 |
Why?
| | Mental Recall | 3 | 2007 | 222 | 0.100 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2013 | 36 | 0.100 |
Why?
| | Anxiety | 3 | 2022 | 1127 | 0.100 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 174 | 0.100 |
Why?
| | Vocalization, Animal | 2 | 2024 | 28 | 0.100 |
Why?
| | Angiostrongylus cantonensis | 1 | 2013 | 3 | 0.100 |
Why?
| | Strongylida Infections | 1 | 2013 | 8 | 0.100 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2014 | 153 | 0.100 |
Why?
| | Longitudinal Studies | 3 | 2025 | 2950 | 0.100 |
Why?
| | Thiazoles | 1 | 2013 | 139 | 0.090 |
Why?
| | Pregnancy | 3 | 2013 | 7197 | 0.090 |
Why?
| | Functional Laterality | 4 | 2009 | 242 | 0.090 |
Why?
| | MAP Kinase Signaling System | 1 | 2014 | 306 | 0.090 |
Why?
| | Meningitis | 1 | 2013 | 80 | 0.090 |
Why?
| | Down Syndrome | 2 | 2022 | 525 | 0.080 |
Why?
| | Genotype | 3 | 2022 | 1853 | 0.080 |
Why?
| | Dopaminergic Neurons | 1 | 2011 | 68 | 0.080 |
Why?
| | Disks Large Homolog 4 Protein | 2 | 2009 | 18 | 0.080 |
Why?
| | Presynaptic Terminals | 2 | 2009 | 89 | 0.080 |
Why?
| | Cellular Reprogramming | 1 | 2011 | 99 | 0.080 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 452 | 0.080 |
Why?
| | Eosinophilia | 1 | 2013 | 223 | 0.080 |
Why?
| | Leukoencephalopathies | 1 | 2010 | 24 | 0.080 |
Why?
| | Prospective Studies | 6 | 2022 | 8039 | 0.080 |
Why?
| | Nootropic Agents | 1 | 2010 | 30 | 0.080 |
Why?
| | Enzyme Inhibitors | 1 | 2013 | 821 | 0.080 |
Why?
| | Dominance, Cerebral | 1 | 1989 | 56 | 0.080 |
Why?
| | Guanylate Kinases | 1 | 2009 | 13 | 0.080 |
Why?
| | Cross-Over Studies | 2 | 2025 | 607 | 0.070 |
Why?
| | Cysts | 1 | 2010 | 112 | 0.070 |
Why?
| | Thrombophilia | 1 | 2009 | 89 | 0.070 |
Why?
| | Diagnosis, Differential | 3 | 2006 | 1507 | 0.070 |
Why?
| | Mathematical Concepts | 1 | 2009 | 36 | 0.070 |
Why?
| | Language Disorders | 2 | 2007 | 29 | 0.070 |
Why?
| | Pyridines | 1 | 2013 | 607 | 0.070 |
Why?
| | Receptors, Cholinergic | 1 | 2008 | 41 | 0.070 |
Why?
| | Reaction Time | 2 | 2009 | 438 | 0.070 |
Why?
| | Biomarkers | 3 | 2021 | 4283 | 0.070 |
Why?
| | A Kinase Anchor Proteins | 1 | 2009 | 70 | 0.070 |
Why?
| | Prognosis | 3 | 2022 | 4323 | 0.070 |
Why?
| | Aged, 80 and over | 5 | 2010 | 8326 | 0.070 |
Why?
| | Uncertainty | 1 | 2009 | 147 | 0.070 |
Why?
| | Cells, Cultured | 7 | 2017 | 4127 | 0.070 |
Why?
| | Exploratory Behavior | 1 | 2008 | 85 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2006 | 3619 | 0.070 |
Why?
| | Gerbillinae | 3 | 2017 | 72 | 0.070 |
Why?
| | Age of Onset | 2 | 2025 | 554 | 0.070 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2009 | 456 | 0.070 |
Why?
| | Atrophy | 2 | 2001 | 199 | 0.070 |
Why?
| | Conditioning, Classical | 1 | 2008 | 120 | 0.060 |
Why?
| | Mossy Fibers, Hippocampal | 1 | 2007 | 12 | 0.060 |
Why?
| | Vertebral Artery Dissection | 1 | 2007 | 30 | 0.060 |
Why?
| | Shy-Drager Syndrome | 1 | 2007 | 1 | 0.060 |
Why?
| | Jejunum | 1 | 2007 | 37 | 0.060 |
Why?
| | Periodicity | 1 | 2007 | 58 | 0.060 |
Why?
| | Games, Experimental | 1 | 2007 | 13 | 0.060 |
Why?
| | Soccer | 1 | 2007 | 39 | 0.060 |
Why?
| | Glutens | 1 | 2007 | 60 | 0.060 |
Why?
| | Strontium | 3 | 2017 | 14 | 0.060 |
Why?
| | Qualitative Research | 2 | 2025 | 1677 | 0.060 |
Why?
| | Neuromuscular Diseases | 1 | 2008 | 146 | 0.060 |
Why?
| | Antibodies | 1 | 2008 | 398 | 0.060 |
Why?
| | Cross-Linking Reagents | 1 | 2007 | 197 | 0.060 |
Why?
| | Football | 1 | 2007 | 89 | 0.060 |
Why?
| | Fibroblasts | 1 | 2011 | 1023 | 0.060 |
Why?
| | Chromosome Mapping | 1 | 2007 | 509 | 0.060 |
Why?
| | Immunohistochemistry | 2 | 2007 | 1710 | 0.060 |
Why?
| | Bumetanide | 1 | 2005 | 5 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 738 | 0.060 |
Why?
| | Secondary Prevention | 1 | 2007 | 256 | 0.060 |
Why?
| | Sodium Potassium Chloride Symporter Inhibitors | 1 | 2005 | 17 | 0.060 |
Why?
| | Organ of Corti | 1 | 2005 | 14 | 0.060 |
Why?
| | Diuretics | 1 | 2005 | 68 | 0.060 |
Why?
| | Hair Cells, Auditory | 1 | 2005 | 45 | 0.060 |
Why?
| | Auditory Pathways | 1 | 2005 | 53 | 0.060 |
Why?
| | Fear | 1 | 2008 | 367 | 0.050 |
Why?
| | Language | 1 | 2008 | 323 | 0.050 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2007 | 539 | 0.050 |
Why?
| | Statistics, Nonparametric | 1 | 2005 | 432 | 0.050 |
Why?
| | Microcephaly | 1 | 2025 | 105 | 0.050 |
Why?
| | Pilot Projects | 2 | 2012 | 1896 | 0.050 |
Why?
| | Tomography, Emission-Computed | 1 | 2004 | 71 | 0.050 |
Why?
| | Ion Channel Gating | 1 | 2005 | 94 | 0.050 |
Why?
| | Length of Stay | 1 | 2010 | 1348 | 0.050 |
Why?
| | Simplexvirus | 1 | 2004 | 82 | 0.050 |
Why?
| | Encephalitis, Viral | 1 | 2004 | 45 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2025 | 2030 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5891 | 0.050 |
Why?
| | Sequence Deletion | 1 | 2024 | 191 | 0.050 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2024 | 125 | 0.050 |
Why?
| | Cannabidiol | 1 | 2026 | 142 | 0.050 |
Why?
| | Odorants | 1 | 2024 | 115 | 0.050 |
Why?
| | Sodium | 1 | 2005 | 198 | 0.050 |
Why?
| | Nerve Net | 1 | 2007 | 284 | 0.050 |
Why?
| | Brain Waves | 1 | 2024 | 45 | 0.050 |
Why?
| | Failure to Thrive | 1 | 2023 | 28 | 0.050 |
Why?
| | Herpes Simplex | 1 | 2004 | 98 | 0.050 |
Why?
| | Muscle Hypotonia | 1 | 2023 | 33 | 0.050 |
Why?
| | Rare Diseases | 1 | 2024 | 116 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2005 | 782 | 0.050 |
Why?
| | Biopsy | 1 | 2007 | 1081 | 0.050 |
Why?
| | Smell | 1 | 2024 | 127 | 0.050 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2004 | 161 | 0.050 |
Why?
| | Radiopharmaceuticals | 1 | 2004 | 207 | 0.050 |
Why?
| | Thirst | 1 | 2003 | 4 | 0.050 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2023 | 73 | 0.050 |
Why?
| | Stereotypic Movement Disorder | 1 | 2003 | 10 | 0.050 |
Why?
| | Dronabinol | 1 | 2026 | 249 | 0.050 |
Why?
| | Vigabatrin | 1 | 2023 | 19 | 0.050 |
Why?
| | Electric Conductivity | 2 | 2004 | 85 | 0.050 |
Why?
| | Third Ventricle | 1 | 2003 | 16 | 0.050 |
Why?
| | Factor Analysis, Statistical | 1 | 2024 | 290 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2023 | 3125 | 0.050 |
Why?
| | Drinking | 1 | 2003 | 44 | 0.050 |
Why?
| | Protein Binding | 3 | 2016 | 2250 | 0.050 |
Why?
| | Syndactyly | 1 | 2022 | 10 | 0.050 |
Why?
| | Longevity | 1 | 2024 | 175 | 0.050 |
Why?
| | Aggression | 1 | 2004 | 178 | 0.050 |
Why?
| | Neurologic Examination | 1 | 2003 | 132 | 0.050 |
Why?
| | Neurons, Afferent | 1 | 2023 | 102 | 0.050 |
Why?
| | Cell Differentiation | 1 | 2010 | 2045 | 0.050 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2023 | 122 | 0.050 |
Why?
| | Miniature Postsynaptic Potentials | 2 | 2014 | 10 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2003 | 252 | 0.040 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 116 | 0.040 |
Why?
| | Chromosome Aberrations | 1 | 2022 | 164 | 0.040 |
Why?
| | Mammals | 1 | 2023 | 296 | 0.040 |
Why?
| | Patient Acuity | 1 | 2021 | 48 | 0.040 |
Why?
| | Anthropometry | 1 | 2022 | 205 | 0.040 |
Why?
| | Comorbidity | 2 | 2022 | 1659 | 0.040 |
Why?
| | Intestinal Mucosa | 1 | 2007 | 675 | 0.040 |
Why?
| | Artifacts | 1 | 2001 | 143 | 0.040 |
Why?
| | Time-to-Treatment | 1 | 2023 | 250 | 0.040 |
Why?
| | Linguistics | 1 | 2000 | 27 | 0.040 |
Why?
| | Motor Skills Disorders | 1 | 2000 | 25 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1755 | 0.040 |
Why?
| | RNA Interference | 2 | 2014 | 473 | 0.040 |
Why?
| | Neural Inhibition | 1 | 2001 | 178 | 0.040 |
Why?
| | Data Interpretation, Statistical | 1 | 2022 | 369 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 482 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 497 | 0.040 |
Why?
| | Cerebral Palsy | 1 | 2022 | 137 | 0.040 |
Why?
| | Forecasting | 1 | 2001 | 391 | 0.040 |
Why?
| | Evoked Potentials, Auditory | 1 | 2021 | 181 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 4 | 2004 | 2772 | 0.040 |
Why?
| | Head Injuries, Closed | 1 | 1999 | 50 | 0.040 |
Why?
| | Electrocardiography | 1 | 2022 | 669 | 0.040 |
Why?
| | tau Proteins | 1 | 2020 | 115 | 0.040 |
Why?
| | Vesicular Transport Proteins | 1 | 1999 | 85 | 0.040 |
Why?
| | Neurology | 1 | 2020 | 115 | 0.030 |
Why?
| | Inflammation | 1 | 2009 | 2883 | 0.030 |
Why?
| | Cost of Illness | 1 | 2020 | 324 | 0.030 |
Why?
| | Chronic Disease | 1 | 2004 | 1816 | 0.030 |
Why?
| | Risk Assessment | 1 | 2007 | 3759 | 0.030 |
Why?
| | Amyloid beta-Peptides | 1 | 2020 | 248 | 0.030 |
Why?
| | Benzothiadiazines | 1 | 2017 | 2 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2021 | 909 | 0.030 |
Why?
| | 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2017 | 11 | 0.030 |
Why?
| | Nifedipine | 1 | 2017 | 27 | 0.030 |
Why?
| | Risk Factors | 3 | 2009 | 10874 | 0.030 |
Why?
| | Family | 1 | 2022 | 687 | 0.030 |
Why?
| | Walking | 1 | 2022 | 542 | 0.030 |
Why?
| | Dipeptides | 1 | 2017 | 56 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2025 | 2355 | 0.030 |
Why?
| | Emotions | 1 | 2022 | 579 | 0.030 |
Why?
| | Quinoxalines | 1 | 2017 | 64 | 0.030 |
Why?
| | Language Tests | 2 | 2007 | 23 | 0.030 |
Why?
| | Calcium Channel Blockers | 1 | 2017 | 166 | 0.030 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 2 | 2009 | 105 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2016 | 302 | 0.030 |
Why?
| | Awareness | 1 | 1997 | 111 | 0.030 |
Why?
| | Models, Biological | 1 | 2023 | 1815 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 2018 | 328 | 0.030 |
Why?
| | Brain Neoplasms | 1 | 2005 | 1329 | 0.030 |
Why?
| | Carrier Proteins | 1 | 1999 | 733 | 0.030 |
Why?
| | Neurocognitive Disorders | 1 | 1995 | 33 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2005 | 140 | 0.030 |
Why?
| | Multiple Sclerosis | 1 | 2001 | 488 | 0.030 |
Why?
| | Adenoviridae | 1 | 1996 | 199 | 0.030 |
Why?
| | Dendritic Cells | 1 | 1998 | 499 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2020 | 779 | 0.030 |
Why?
| | Gene Transfer Techniques | 1 | 1996 | 186 | 0.030 |
Why?
| | Genetic Vectors | 1 | 1996 | 335 | 0.030 |
Why?
| | Electric Stimulation | 2 | 2005 | 277 | 0.030 |
Why?
| | Peptides | 2 | 2016 | 993 | 0.030 |
Why?
| | Mollusk Venoms | 1 | 1993 | 1 | 0.030 |
Why?
| | Ibotenic Acid | 1 | 1993 | 5 | 0.030 |
Why?
| | 2-Amino-5-phosphonovalerate | 1 | 1993 | 12 | 0.030 |
Why?
| | Genes, Reporter | 1 | 2014 | 276 | 0.020 |
Why?
| | Heart Diseases | 1 | 1997 | 342 | 0.020 |
Why?
| | Pyramidal Tracts | 1 | 1993 | 30 | 0.020 |
Why?
| | Neural Pathways | 2 | 2005 | 312 | 0.020 |
Why?
| | Point Mutation | 1 | 2014 | 242 | 0.020 |
Why?
| | DNA, Helminth | 1 | 2013 | 26 | 0.020 |
Why?
| | Magnesium | 1 | 1993 | 156 | 0.020 |
Why?
| | Reading | 1 | 1994 | 135 | 0.020 |
Why?
| | Video Recording | 2 | 2005 | 218 | 0.020 |
Why?
| | Incidence | 2 | 2010 | 2915 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2014 | 762 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2014 | 407 | 0.020 |
Why?
| | Cerebral Infarction | 2 | 1989 | 47 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2009 | 907 | 0.020 |
Why?
| | Cyclic GMP | 1 | 2012 | 90 | 0.020 |
Why?
| | Cerebellum | 1 | 1994 | 224 | 0.020 |
Why?
| | Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2011 | 8 | 0.020 |
Why?
| | Transfection | 2 | 2009 | 925 | 0.020 |
Why?
| | Memory, Episodic | 1 | 2012 | 55 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2014 | 632 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2012 | 207 | 0.020 |
Why?
| | Peptides, Cyclic | 1 | 1993 | 275 | 0.020 |
Why?
| | Aging | 2 | 2021 | 1940 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2014 | 468 | 0.020 |
Why?
| | Levodopa | 1 | 1991 | 41 | 0.020 |
Why?
| | SOXB1 Transcription Factors | 1 | 2011 | 67 | 0.020 |
Why?
| | Trihexyphenidyl | 1 | 1991 | 1 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2016 | 2189 | 0.020 |
Why?
| | Ginkgo biloba | 1 | 2010 | 11 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2003 | 2962 | 0.020 |
Why?
| | Aphasia, Wernicke | 1 | 1989 | 2 | 0.020 |
Why?
| | Anomia | 1 | 1989 | 2 | 0.020 |
Why?
| | Aphasia, Broca | 1 | 1989 | 3 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1049 | 0.020 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2009 | 92 | 0.020 |
Why?
| | Psychotropic Drugs | 1 | 2010 | 78 | 0.020 |
Why?
| | Factor VIII | 1 | 2009 | 105 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 409 | 0.020 |
Why?
| | Dopamine | 1 | 2011 | 295 | 0.020 |
Why?
| | Long-Term Care | 1 | 2010 | 117 | 0.020 |
Why?
| | Population Dynamics | 1 | 2010 | 158 | 0.020 |
Why?
| | Germ Cells | 1 | 2009 | 65 | 0.020 |
Why?
| | Calcineurin | 1 | 2009 | 105 | 0.020 |
Why?
| | Pyrimidines | 1 | 2012 | 520 | 0.020 |
Why?
| | Dendritic Spines | 1 | 2009 | 70 | 0.020 |
Why?
| | Austria | 1 | 2008 | 8 | 0.020 |
Why?
| | Luminescent Proteins | 1 | 2009 | 186 | 0.020 |
Why?
| | Switzerland | 1 | 2008 | 46 | 0.020 |
Why?
| | Netherlands | 1 | 2008 | 82 | 0.020 |
Why?
| | Probability | 1 | 2009 | 310 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2009 | 284 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2008 | 162 | 0.020 |
Why?
| | Plant Extracts | 1 | 2010 | 188 | 0.020 |
Why?
| | Germany | 1 | 2008 | 138 | 0.020 |
Why?
| | Homeodomain Proteins | 1 | 2011 | 525 | 0.020 |
Why?
| | Antipsychotic Agents | 1 | 2010 | 215 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 422 | 0.020 |
Why?
| | Picrotoxin | 1 | 2007 | 12 | 0.020 |
Why?
| | GABA Antagonists | 1 | 2007 | 34 | 0.020 |
Why?
| | Life Style | 1 | 2010 | 483 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 1988 | 106 | 0.020 |
Why?
| | Alcoholism | 1 | 1994 | 821 | 0.020 |
Why?
| | Cerebral Hemorrhage | 1 | 1988 | 125 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2009 | 850 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2010 | 1046 | 0.020 |
Why?
| | Brain Mapping | 1 | 1989 | 536 | 0.010 |
Why?
| | Multicenter Studies as Topic | 1 | 2008 | 411 | 0.010 |
Why?
| | Electromyography | 1 | 2008 | 419 | 0.010 |
Why?
| | Sodium-Potassium-Chloride Symporters | 1 | 2005 | 9 | 0.010 |
Why?
| | Solute Carrier Family 12, Member 2 | 1 | 2005 | 7 | 0.010 |
Why?
| | Phenobarbital | 1 | 2005 | 21 | 0.010 |
Why?
| | United States | 1 | 2023 | 16115 | 0.010 |
Why?
| | Amino Acids | 1 | 2010 | 521 | 0.010 |
Why?
| | Electric Capacitance | 1 | 2005 | 6 | 0.010 |
Why?
| | Turtles | 1 | 2005 | 14 | 0.010 |
Why?
| | Epilepsy, Tonic-Clonic | 1 | 2005 | 6 | 0.010 |
Why?
| | Sclerosis | 1 | 2005 | 11 | 0.010 |
Why?
| | Egtazic Acid | 1 | 2005 | 37 | 0.010 |
Why?
| | Rats, Long-Evans | 1 | 2005 | 128 | 0.010 |
Why?
| | Videotape Recording | 1 | 2005 | 37 | 0.010 |
Why?
| | Medication Adherence | 1 | 2010 | 543 | 0.010 |
Why?
| | Synaptic Vesicles | 1 | 2005 | 40 | 0.010 |
Why?
| | Cadmium | 1 | 2005 | 68 | 0.010 |
Why?
| | Head Movements | 1 | 2005 | 37 | 0.010 |
Why?
| | Basal Ganglia | 1 | 2005 | 57 | 0.010 |
Why?
| | Aspartic Acid | 1 | 2005 | 87 | 0.010 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2005 | 157 | 0.010 |
Why?
| | Neural Conduction | 1 | 2005 | 92 | 0.010 |
Why?
| | Rotation | 1 | 2005 | 125 | 0.010 |
Why?
| | Chelating Agents | 1 | 2005 | 72 | 0.010 |
Why?
| | Monte Carlo Method | 1 | 2005 | 153 | 0.010 |
Why?
| | Reference Values | 2 | 1999 | 797 | 0.010 |
Why?
| | Acyclovir | 1 | 2004 | 97 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2011 | 2499 | 0.010 |
Why?
| | Posture | 1 | 2005 | 198 | 0.010 |
Why?
| | Drug Interactions | 1 | 2005 | 404 | 0.010 |
Why?
| | Vomiting | 1 | 2004 | 132 | 0.010 |
Why?
| | Transcription Factors | 1 | 2011 | 1733 | 0.010 |
Why?
| | Attention | 1 | 2007 | 463 | 0.010 |
Why?
| | Fever | 1 | 2004 | 317 | 0.010 |
Why?
| | Monitoring, Intraoperative | 1 | 2003 | 67 | 0.010 |
Why?
| | Diagnostic Imaging | 1 | 2005 | 342 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2002 | 529 | 0.010 |
Why?
| | Computer Simulation | 1 | 2005 | 1026 | 0.010 |
Why?
| | N-Ethylmaleimide-Sensitive Proteins | 1 | 1999 | 5 | 0.010 |
Why?
| | Blood Pressure | 1 | 2007 | 1782 | 0.010 |
Why?
| | Water | 1 | 2003 | 468 | 0.010 |
Why?
| | Prevalence | 1 | 2007 | 2855 | 0.010 |
Why?
| | Colorado | 1 | 2009 | 4572 | 0.010 |
Why?
| | Rats, Wistar | 1 | 1998 | 449 | 0.010 |
Why?
| | Dizocilpine Maleate | 1 | 1996 | 24 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1996 | 182 | 0.010 |
Why?
| | beta-Galactosidase | 1 | 1996 | 76 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1996 | 1367 | 0.010 |
Why?
| | Kinetics | 1 | 1996 | 1605 | 0.010 |
Why?
| | Cell Survival | 1 | 1996 | 1094 | 0.010 |
Why?
| | Receptors, Dopamine | 1 | 1991 | 19 | 0.010 |
Why?
| | Brain Concussion | 1 | 1999 | 641 | 0.010 |
Why?
| | Intelligence Tests | 1 | 1991 | 55 | 0.010 |
Why?
| | Psychological Tests | 1 | 1991 | 132 | 0.000 |
Why?
| | Frontal Lobe | 1 | 1991 | 160 | 0.000 |
Why?
| | Kidney | 1 | 1996 | 1498 | 0.000 |
Why?
| | Cerebral Ventricles | 1 | 1988 | 55 | 0.000 |
Why?
| | Hypertension | 1 | 1988 | 1273 | 0.000 |
Why?
|
|
Benke's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|